Home > Companies > ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

acadia-pharm.com

ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (CNS) disorders. All of ACADIA's product candidates emanate from internal discoveries. We believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. ACADIA’s history is rooted in science and strong leadership in CNS research. Our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. Since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. ACADIA is headquartered in San Diego. The city represents the second largest biotechnology industry cluster in the United States, home to over 400 companies, as well as the Salk Institute for Biological Studies and the Scripps Research Institute.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

Related News

CPI PARTNERS WITH RSC TO TACKLE CHEMICAL SCIENCE CHALLENGES

The Chemical Engineer | February 13, 2020

TECHNOLOGY innovation centre CPI has partnered with the Royal Society of Chemistry (RSC) as part of the learned society’s Synergy programme. The programme aims to promote cross-industry collaboration to enable participating companies to tackle complex chemical science challenges that can hinder development. It can be difficult for companies facing chemistry-related problems early in the innovation process to source the expertise needed to identify commercially-viable solutions. The issue i...

Products and Technologies, Market Outlook

HENRY RESOURCES AND VIEWPOINT WITH DENNIS QUAID COLLABORATE TO SHOWCASE INNOVATIONS IN THE OIL & GAS INDUSTRY

prweb | June 23, 2023

Viewpoint with Dennis Quaid, a highly acclaimed short-form series known for insightful discussions, is excited to announce its collaboration with Henry Resources, a prominent name in the oil and gas sector. This unique partnership aims to showcase key developments and innovations in the oil and gas industry, bringing attention to advancements that optimize solutions and promote sustainability. Henry Resources, with its rich experience in exploration, production, and development,...

Chemical Management, Market Outlook

SP CHEMICALS SELECTS LUMMUS' CATOFIN AND NOVOLEN TECHNOLOGIES

prnewswire | April 06, 2023

Lummus Technology, a global provider of process technologies and value-driven energy solutions, announced an integrated technology award from SP Chemicals and its subsidiary SP Olefins. SP Chemicals will license Lummus' CATOFIN® technology for a new 800 KTA propane dehydrogenation (PDH) unit, and SP Olefins will license Lummus' Novolen® technology for a new 400 KTA polypropylene (PP) unit. Both units will be located at SP Chemicals' complex in Jiangsu Province, China. Read More

Chemical Management

SASOL, HALDOR TOPSØE EXPAND G2LTM LICENSING COLLABORATION TO GROW SUSTAINABLE SYNTHETIC FUELS AND CHEMICALS GLOBALLY

Sasol &amp; Haldor Topsoe A/S | September 16, 2021

Haldor Topsøe and Sasol have expanded collaboration to jointly license and develop their technologies for sustainable liquid fuels and chemicals production through Fischer-Tropsch (FT) technology. Sasol and Topsøe currently offer integrated end-to-end solutions to produce synthetic fuels and chemicals. Topsøe's SynCOR™ and Sasol's Low Temperature Fischer-TropschTM technologies have been licensed into Gas-to-Liquid (GTL) ventures, most recently Uz...